Addition of nab-paclitaxel to gemcitabine/cisplatin does not

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

Related Keywords

Minnesota , United States , Texas , American , Carol Aghajanian , Howards Hochster , Robink Kelley , Khalid Matin , Emily Henderson , Puneet Cheema , Jaykumar Thumar , Rachna Shroff , Bristol Myers Squibb , E Gabriela Chiorean , Renukav Iyer , Katherine Guthrie , Anujk Patel , Anthonyb El Khoueiry , Sloan Kettering , Philipa Philip , Aaronj Scott , Milind Javle , Lauraw Goff , Amit Mahipal , National Cancer Institute , Celgene Corporation , Siteman Cancer Center , Data Management Center , Fred Hutchinson Cancer Center , Washington University , Cancer Research Network , University Of Washington School Medicine , Roswell Park Cancer Institute , Vanderbilt University , Rutgers Cancer Institute , Massey Cancer Center , Yale University , National Clinical Trials Network , University Of Texas Md Anderson Cancer Center , National Institutes Of Health , Ingram Cancer Center , University Of Arizona Cancer Center , Dana Farber Harvard Cancer Center , Norris Comprehensive Cancer Center , Case Western Reserve University , Northwestern University , University Of Arizona , Research Network , Cancers Symposium , American Society , Clinical Oncology , Uarizona Cancer , Discovery Industry Focus , National Institutes , Clinical Trials Network , Henry Ford Cancer Institute , Wayne State University , Mayo Clinic , Cancer Center , Aparna Kalyan , Memorial Sloan Kettering , Benjamin Tan , Metro Minnesota Community Oncology Research , Saint John , Harvard Cancer Center , Washington School , Rutgers Cancer , Cancer , Paclitaxel , Adenocarcinoma , Cholangiocarcinoma , Cisplatin , Gemcitabine , Medicine , Ncology , Research ,